2與吉西他濱1 000 mg/m2聯(lián)合化療.單藥治療組37例,吉西他濱單藥600 mg/m2化療,療程均為4個周期(每個周期間隔21 d).26周進(jìn)行近期療效及安全性分析,隨訪2年觀察患者生存期.結(jié)果 (1)疾病控制率(DCR):聯(lián)合治療組為62.86%,單藥治療組為51.35%,兩組比較差異無統(tǒng)計學(xué)意義(χ2=0.97,P=0.32);但早期患者聯(lián)合治療組DCR(85.71%)優(yōu)于單藥治療組(56.52%),兩組比較差異有統(tǒng)計學(xué)意義(χ2=4.49,P=0.034);(2)生存時間:聯(lián)合治療組中位生存時間為8.9個月,單藥治療組為8.1個月,兩組比較無統(tǒng)計學(xué)差異.(3)不良反應(yīng):聯(lián)合治療組粒細(xì)胞、血小板減少和肝功能異常的發(fā)生率(60.2%、53.9%、54.2%)均高于單藥組(32.1%、24.3%、27.0%),差異有統(tǒng)計學(xué)意義(P <0.05).結(jié)論 培美曲塞與吉西他濱聯(lián)合化療可以提高早期胰腺癌患者的療效,同時也相應(yīng)地增加對骨髓造血功能的抑制和肝損傷的風(fēng)險.;Objective To observe the different effects of Pemetrexed combined with Gemcitabine vs Gemcitabine alone in treatment of pancreatic adenocarcinoma, and to optimize the chemotherapy further. Methods The pancreatic cancer patients (72 cases) with non-surgical treatment were divided into two groups. The 35 patients in combined group were administered with Pemetrexed 600 mg/m2combined with Gemcitabine 1 000 mg/m2, and the 37 patients in monotherapy group accepted Gemcitabine single for 4 cycles (Q21days). The shot-term efficacy and safety were observed and analysed at 26 weeks. The survival time of patients was followed up for 2 years. Results (1) The disease control rate (DCR) of two groups had no significant difference (χ2= 0.97, P= 0.32), and that of combined group was 62.86%, monotherapy group was 51.35%. But the DCR of combined group was higher than that of the other group in the early stage patients (85.71% vs 56.52%), with significant difference (χ2= 4.49, P= 0.034). (2) The medium survival time was 8.9 months in combined group and 8.1 months in monotherapy group. There was no difference between two groups. (3) The incidence rate of neutrophilic granulocytopenia, thrombocytopenia, and liver function damage in combined group (60.2%, 53.9%, and 54.2%) were higher than those in the other group (32.1%, 24.3%, and 27.0%). There was significant difference between two groups, but the incidence rate of the whole body and the digestive tract symptoms in two groups had no difference. Conclusion Pemetrexed combined with Gemcitabine chemotherapy could improve the curative effect of early pancreatic carcinoma vs Gemcitabine singe chemotherapy, however, increased the inhibition of bone marrow hematopoietic function and live function damage meanwhile."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2015年第38卷第5期 >2015,38(5):538-541. DOI:10.7501/j.issn.1674-6376.2015.05.015
上一篇 | 下一篇

培美曲塞聯(lián)合吉西他濱與吉西他濱單藥治療胰腺癌患者的臨床對照研究

Controlled clinical study on effect of Pemetrexed combined with Gemcitabine contrasted with Gemcitabine in pancreatic adenocarcinoma

發(fā)布日期:2015-09-29
您是第位訪問者
藥物評價研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031